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RESEARCH ARTICLE
Structural determinants 
influencing halogen bonding: a case study 
on azinesulfonamide analogs of aripiprazole 
as 5-HT1A, 5-HT7, and  D2 receptor ligands
Krzysztof Marciniec1* , Rafał Kurczab2, Maria Książek3, Ewa Bębenek1, Elwira Chrobak1, Grzegorz Satała2, 
Andrzej J. Bojarski2, Joachim Kusz3 and Paweł Zajdel4
Abstract 
A series of azinesulfonamide derivatives of long-chain arylpiperazines with variable-length alkylene spacers between 
sulfonamide and 4-arylpiperazine moiety is designed, synthesized, and biologically evaluated. In vitro methods 
are used to determine their affinity for serotonin 5-HT1A, 5-HT6, 5-HT7, and dopamine  D2 receptors. X-ray analysis, 
two-dimensional NMR conformational studies, and docking into the 5-HT1A and 5-HT7 receptor models are then 
conducted to investigate the conformational preferences of selected serotonin receptor ligands in different environ-
ments. The bent conformation of tetramethylene derivatives is found in a solid state, in dimethyl sulfoxide, and as 
a global energy minimum during conformational analysis in a simulated water environment. Furthermore, ligand 
geometry in top-scored complexes is also bent, with one torsion angle in the spacer (τ2) in synclinal conformation. 
Molecular docking studies indicate the role of halogen bonding in complexes of the most potent ligands and target 
receptors.
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Introduction
Long-chain arylpiperazines (LCAPs) constitute one of 
the largest classes of serotonin (5-HT), and dopamine (D) 
receptor ligands, and exhibit diverse actions on the cen-
tral nervous system (CNS) [1–4]. Among this vast group, 
we recently developed LCAP analogs of aripiprazole, with 
quinoline- or isoquinoline-sulfamoyl moieties, which dis-
played a 5-HT/D multi-receptor binding profile [5–8]. 
Structure–activity relationship studies have revealed that 
the observed receptor binding and functional profiles 
depend on the type of substituent in the arylpiperazine 
moiety, and the length and conformation of the aliphatic 
linker and the terminal fragment. Completing the charac-
terization of this class of ligands, the selected compounds 
show potent antidepressant or antipsychotic activity with 
pro-cognitive properties [5–8].
In recent years, many research groups have explored 
monochloro- or dichloro-phenylpiperazine as a privi-
leged structure for the optimization of CNS-active 
compounds providing with such psychotropic drugs as 
aripiprazole, trazodone, cariprazine [9–12] (Fig.  1). In 
the following years, the first reports were published on 
the engagement of halogen atoms in stabilization of the 
ligand–receptor complex within compounds targeting 
the central nervous system, especially 5-HT1A, 5-HT7, 
and  D2 receptors [13].
Some controversy has arisen concerning the role of the 
alkylene linker, usually composed of two to five carbon 
atoms as to whether it actively participates in binding 
or simply acts as a distance arm providing a chain [14]. 
Nevertheless, due to the highly flexible nature of a linker, 
various attempts have been made to determine the bioac-
tive conformation of LCAPs.
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Assuming that active conformations of LCAPs are 
closely related to those in solution or in solid state, two-
dimensional nuclear magnetic resonance (2D NMR) and 
crystallographic methods have often been applied to 
approximate the bioactive structure [15–20]. These 2D 
NMR studies indicate that compounds with an alkylene 
spacer can adopt extended, bent, or folded conformations 
[15–17]. In contrast, analysis of the Cambridge Structural 
Database (CSD) indicates that linear geometries are pre-
dominant (see Additional file  1: Table  S1). Furthermore, 
molecular modeling simulations (conformational analysis 
and docking experiments) have provided equivocal results 
on the different bioactive conformations of LCAPs.
Extending studies on verification of the impact of halo-
gen bond, alkylene linker length, and localization of the 
sulfonamide group in the azine moiety, a limited series 
of isoquinoline-sulfonamide derivatives of LCAP were 
designed (Fig. 1). Following our previous studies [5] sug-
gesting the preferential position of the sulfonamide group 
in the β-position of the azinyl moiety, regardless of sul-
fonamide group localization in pyridine or benzene rings, 
the 3-isoquinolyl moiety was selected for the design of 
new aripiprazole analogs. Herein we report on the syn-
thesis of selected azinesulfonamides and their X-ray 
structure analysis, followed by NMR experiments, and 
in silico molecular modeling. In doing so, we attempt to 
understand the conformational orientation of chemical 
sub-structures favorable for interaction with 5-HT1A and 
5-HT7Rs.
Results and discussion
Source of compounds
Azinesulfonamide analogs of aripiprazole 1–6 were 
prepared according to previously reported procedures 
(Scheme 1) [5, 6].
The synthesis of compounds 1–6 was carried out 
by reaction of the primary amines (9–13) with 3-iso-
quinolinesulfonyl chloride (7) or 7-quinolinesulfo-
nyl chloride (8) in the presence of Hunig’s base. The 
azinesulfonyl chlorides 7 and 8 were prepared from 
3-bromoisoquinoline or 7-chloroquinoline, respectively, 
according to the previously reported method [5]. For the 
pharmacological evaluation, free bases were converted 
into their water-soluble hydrochloride salts 1–6. The 
spectroscopic data (NMR and MS) of compounds 3, 5, 
and 6 were identical to those previously reported [5].
Structure–activity relationship studies
Following our previous studies [5], which suggest a pref-
erential position of sulfonamide group in the β-position 
of the azinyl moiety (confirming the structural analogy 
for the dihydroquinolin-7-yl-2-one core in aripipra-
zole), 3-isoquinolyl moiety was selected to design the 
analogs of aripiprazole. In a series of new isoquinolinyl 
derivatives, we also focused our attention on the type of 
halogen substitution in a phenylpiperazine fragment to 
determine the role of the halogen bond in ligand com-
plexes and target receptors.
The term “halogen bond” refers to the non-covalent 
interactions of halogen atoms X in one molecule with a 
negative site on another. X can be chlorine, bromine or 
iodine, but not fluorine. It is increasingly recognized that 
halogen bonding occurs in various biological systems and 
processes, and can be utilized effectively in drug design 
[21, 22]. Subsequently, regarding preliminary studies on 
the engagement of halogens in the interaction of LCAP 
derivatives with a partially rigidified alkylene spacer with 
serotonin receptors [8], our interest was focused on the 
impact of halogen in binding of compounds 2–6 with 
5-HT1A and 5-HT7 receptors.
The unsubstituted analog 1 displayed low affinity for 
all tested receptors (Table 1). Introduction of chlorine in 
the 3-position increased receptors’ affinity up to 3–12-
fold (1 vs 2). These findings are in line with our previous 
study, and reveal that the presence of a chlorine atom in 
the 3-position stabilizes the ligand–receptor complex 
through the formation of a halogen bond with Thr5.39 
residue of 5-HT1A and 5-HT7Rs [8]. Furthermore, intro-
duction of a second chlorine atom in the 2-position of the 
phenylpiperazine yielded compound 3. This modification 
Fig. 1 Chemical structures of atypical antipsychotics aripiprazole, 
trazodone, cariprazine and compounds used in this study
Scheme 1 Synthesis of azinesulfonamides 1–6. Reagents and condi-
tions: (i) DIEA,  CH2Cl2, 0 °C/rt.; (ii) 1 M HCl in dioxane/rt
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did not substantially affect the receptor binding pro-
file in comparison to its 3-chloro counterpart (2 vs 3), 
except for an increase in the affinity for  D2Rs. In contrast, 
replacement of chlorine atoms in the 2- and 3-positions 
with methyl groups (compound 4) decreased the affinity 
for 5-HT1A, and 5-HT7Rs up to twofold (3 vs 4).
Subsequently, we compared the data obtained for 
3-chloro- and 2,3-dimethyl derivatives (2 and 4, respec-
tively) and unsubstituted phenylpiperazine analog 1 with 
those previously reported for their 2,3-dichloro analogs. 
A change of the 3-isoquinolinyl fragment for 7-quinoli-
nyl yielded compound 5, which displayed a two- to three-
fold higher affinity for 5-HT1A, 5-HT6, and 5-HT7Rs, thus 
revealing the 7-quinolinyl fragment as more favorable for 
interaction with 5-HT1ARs. Within the evaluated quino-
line derivatives 5 and 6, shortening of the butylene spacer 
to propylene one, had little influence on the receptor 
profile.
The binding data for  D2 receptors revealed that com-
pound 1, unsubstituted at the phenyl ring, displayed low 
affinity for  D2Rs with Ki equaling 565 nM (Table 1). Intro-
duction of one chlorine atom in the 3-position increased 
affinity for  D2Rs 12-fold, and two chlorine atoms in the 2- 
and 3-positions increased affinity up to 33-fold. As found 
in our previous research [8], replacement of chlorine 
atoms with methyl substituents maintained affinity for 
 D2Rs at the same level. This could suggest a lower impact 
of halogen bonds, as they are less engaged in interaction 
with  D2Rs then in the case of 5-HT1A and 5-HT7Rs. Fur-
thermore, it was found, that the 3-isoquinolinyl fragment 
was less preferable than 7-quinolinyl for interaction with 
 D2Rs (4 vs 5) and shortening of the alkylene linker (from 
4 to 3 methylene units) maintained a high affinity for 
 D2Rs (4 vs 6).
Generally, the compounds selected for extended struc-
tural evaluation may be classified as multimodal seroto-
nin and dopamine receptor ligands with high affinity for 
5-HT1A/5-HT7 and  D2 receptors, and moderate to low 
affinity for 5-HT6 receptors. Significantly, introduction of 
an azinesulfonamide group into the structure of LCAPs, 
decreased their affinity for  D2 receptors compared to ari-
piprazole [8].
Structural analysis
The Cambridge Structural Database (CSD version 5.39, 
November 2017 [23]) was used to search for compounds 
with the following queries: unsubstituted piperazine car-
bon atoms, no additional cyclic arrangements between 
aryl and piperazine moieties with ethylene, propylene, 
and butylene spacers. The search resulted in 36 hits 
(Additional file  1: Table  S2). The piperazine ring in all 
structures deposited in the CSD adopts the chair con-
formation with substituents located equatorially. The 
mutual position of aryl and piperazine rings may be 
described simply by the torsional angle τ and/or dihedral 
angle ф between piperazine plain and the phenyl ring 
(Additional file 1: Figure S1). In the majority of meta- and 
para- substituted derivatives, the phenyl ring is more or 
less coplanar with piperazine (torsion angle values are 
grouped in the vicinity of 0° or 180°, while the dihedral 
angle is far from 90°). At the same time, all ortho-sub-
stituted compounds exhibit noncoplanar conformation. 
The spacers’ conformations vary from fully extended to 
variously bent. Methylene chains predominantly adopt 
the extended form in the crystal. Meanwhile, in aryl-
piperazine salts piperazine nitrogen N1 is protonated 
and interacts with the respective anion through inter-
ionic hydrogen bonds. These interactions establish a 
salt bridge between the molecules, which plays a leading 
Table 1 Binding affinity of the investigated azinesulfonamides 1–6 for 5-HT1A, 5-HT6, 5-HT7, and  D2 receptors
a  Mean Ki values (SEM ± 23%) based on three independent binding experiments
b  Data taken from Ref. [6]
Compound Ki (nM)
a
Azinyl n R 5-HT1A 5-HT6 5-HT7 D2
1 3-isoquinolinyl 2 H 304 1352 245 565
2 3-isoquinolinyl 2 3-Cl 38 436 49 47
3b 3-isoquinolinyl 2 2,3-diCl 34 454 56 17
4 3-isoquinolinyl 2 2,3-diMe 73 916 85 23
5b 7-quinolinyl 2 2,3-diCl 17 301 31 11
6b 7-quinolinyl 1 2,3-diCl 14 257 12 16
Aripiprazole – – 5.6 90 26 0.8
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role in the discussed crystal architecture. In the case of 
solvent-free hydrochlorides,  NH+···Cl−···H–Cspacer inter-
actions form a simple short bridge between more or less 
parallel molecules. Salt bridge elongation was observed 
in a number of structures containing water in the form of 
 NH+···Cl−···H2O···H–Cspacer. Furthermore, these interac-
tions caused important variation in the conformation of 
the alkylene spacer [20, 24].
Most of the above observations concerning the con-
formations of arylpiperazines collected in the CSD are 
self-evident for the five structures investigated in this 
paper. The main difference in the crystal structures of 
compounds 2–6 is the construction of salt bridges. Intro-
duction of the –SO2–NH– sulfonamide fragment pro-
vides two strong proton acceptors and one strong proton 
donor which significantly change inter-ionic interac-
tion in azinesulfonamides 2–6 compared to the crystal 
structures deposited in the CSD. In the case of solvent-
free hydrochlorides, the  NH+···Cl−···H–Nsulfon interac-
tions form a simple short bridge. Salt bridge elongation, 
resulting from water participation, was observed in one 
structure in the form of  NH+···Cl−···H2O···H–Nsulfon in 
5 (Fig. 2).
It should be mentioned that all derivatives 1–6 are 
highly resistant to crystallization and dissolve in most 
solvents; the glassy state is a dominant solid state for 
these derivatives. Therefore, we were fortunate to suc-
cessfully obtain the monocrystals for five analogs of 
LCAPs. It should be pointed out that studying the struc-
ture nonsubstituted at phenyl ring analog 1 was also 
planned; however, owing to the crystal quality only a 
rough structure model was obtained.
In the structure of 2, two molecules were found in 
an independent unit, with the conformation of both 
Fig. 2 Molecular geometry of crystal structures, showing the atom labelling scheme. Dashed lines represent a charge-assisted hydrogen bond 
 NH+···Cl− or  NH+···Cl−···H2O···H–Nsulfon
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molecules being almost identical. Moreover, in the struc-
ture of hydrochloride 5, besides the chlorine anion, a 
water molecule was also found. Significant geometrical 
parameters of the studied structures are summarized in 
Table 2.
In the crystal structures of compounds 2–6 the pipera-
zine ring was in a common chair conformation (with the 
two N-substituents in equatorial positions) as indicated 
by deviations of nitrogen atoms in opposite directions 
from the plane defined by the ring carbons. The result-
ing distances were 0.63 and 0.64  Å for 2, 0.73 and 0.64 
Å for 3, 0.73 and 0.64 Å for 4, 0.72 and 0.62 Å for 5, and 
0.72 and 0.62 Å for 6, respectively, with the second values 
referring to the protonated piperazine nitrogen, substi-
tuted equatorially by the alkylene linker. Accordingly, the 
inter-correlated position of piperazine and aromatic rings 
of the LCAPs may play a crucial role in ligand receptor 
recognition. The arylpiperazine moiety in the 2,3-disub-
stituted at phenyl ring azinesulfonamides 3–5 exhibits 
non-coplanar conformation with the main piperazine 
plane (formed by the atoms C13, C14, C15, and C16) 
and the phenyl inclined by ф = 47.1–62.8°. In the 3-sub-
stituted derivative 2, the phenyl ring is more coplanar 
with the piperazine plane (ф = 20.6°) (Table 2). It is worth 
mentioning that in sulfonamides 5 and 6, the most potent 
5-HT1A and 5-HT7 receptor ligands, the angle between 
the piperazine plane and the phenyl ring reached its 
highest values (51.5° and 62.8° respectively). As a result, 
ability of the chlorine atom to stabilize the ligand–recep-
tor (L–R) complex by the formation of stronger halogen 
bonds is increased compared with compounds 2 and 3. 
Furthermore, the quinolinesulfonamide heterocyclic 
head and phenyl ring in compounds 5 and 6 were essen-
tially planar, while in isoquinolinesulfonamides the phe-
nyl and isoquinoline planes were almost perpendicular to 
each other in the crystals of 3 and 4 (ф = 81.6° and 77.6°, 
respectively).
Special attention was placed upon the conformation of 
the alkylene spacer, due to its significant flexibility. Analy-
sis of similar structures found in the CSD showed that an 
extended conformation of the spacer was favorable (see 
Additional file 1: Table S1). The five new crystallographic 
structures obtained results that differed slightly from the 
protonated analogs of alkylarylpiperazines deposited in 
the CSD. In compound 6, the n-propyl chain adopted a 
bent conformation gauche-trans–trans (for torsion angle 
see Table  2) and in the 2–5 conformation was not fully 
extended. The bending of the chain (gauche conforma-
tion) on the C9–C10 bond was essential for the obtained 
crystal structures (Fig. 3).
The supramolecular organization of the hydrochloride 
2 was based mainly on different weak hydrogen bonds 
of the type C–H···Cl. Additionally one strong hydro-
gen bond between the nitrogen  NH+ and  Cl− anion was 
observed. The molecules were linked by weak hydrogen 
bonds between carbon atoms from the phenylpiperazine 
rings and oxygen atoms from the sulfonamide group. 
Additional file 1: Table S3 contains detailed characteris-
tics of these interactions.
The solid-state conformations of azinesulfonamides 3 
and 4 are stabilized by a system of intermolecular hydro-
gen bonds. The geometric parameters indicate that in 
the crystal structure of compounds 3 and 4, molecules of 
the studied sulfonamides form chains, of the head-to-tail 
type stabilized by salt bridges of  NH+···Cl−···H–Nsulfon 
(Additional file 1: Table S3).
Meanwhile, molecules of sulfonamide 5, as well as sul-
fonamide 6, were joined as a head-to-head type chain 
motif, with intermolecular distance equal to 6.91 Å. The 
Table 2 Selected interatomic distances [Å] and dihedral angles [º]a of the studied compounds
a  For the definition of dihedral angles see Fig. 3
Compound N+···Nsulfon τ1 τ2 τ3 τ4 τ5 τ6 Ф
2 5.47 − 113.7 − 69.0 179.4 − 174.8 53.7 − 147.5 20.6
3 5.48 − 156.3 74.4 − 170.5 − 176.5 − 49.5 159.2 47.1
4 5.48 − 155.7 73.9 − 171.4 − 176.2 − 50.5 158.8 48.0
5 5.00 − 119.3 − 65.1 − 72.7 178.3 − 53.7 − 143.8 62.8
6 4.39 − 102.7 − 68.3 179.7 − 55.1 – 154.6 51.5
Fig. 3 Numbering system used in X-ray and NMR analysis of azine-
sulfonamides with tetramethylene linker. Significant NOE signals were 
also demonstrated
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type of interaction that governs the crystal packing of the 
presented structure is strong hydrogen bonds, in which 
water molecules are involved. The observed hydrogen 
bond motives differ for sulfonamide 5 (Fig.  4), and the 
solvent molecule creates interesting patterns in the crys-
tal lattice. Water molecules form the strong hydrogen 
bonds O–H···Cl−···NH+ and H–O···H–Nsulfon. Moreo-
ver, in the crystal structure of 5, water is a hydrogen bond 
donor with the quinolinesulfonamide oxygen atom acting 
as an acceptor (Additional file 1: Table S3).
The supramolecular organization of hydrochloride 
6 is primarily governed by strong inter-ionic hydrogen 
bonds between the protonated arylpiperazine nitrogen, 
the chlorine anion located in the gap between extended 
molecules and nitrogen of the sulfonamide group (Fig. 4). 
Thus, due to steric and geometrical complementarities, 
parallel molecules of 6 form chains of the head-to-head 
type, with an intermolecular distance equal to 6.82 Å. In 
this arrangement, molecules are joined by salt bridges 
of  NH+···Cl−···H–Nsulfon (graph set notation of C21(8)) 
(Additional file 1: Table S3).
NMR studies
In the solid state, the compound exists in a bent con-
formation with the methylene bridging units in a syn-
clinal–antiperiplanar–antiperiplanar–antiperiplanar 
arrangement for compounds 2–5, and a synclinal–anti-
periplanar–antiperiplanar arrangement for compound 
Fig. 4 Crystal packing of azinesulfonamides 2–6. Hydrogen atoms not involved in the hydrogen bond patterns were removed for clarity
Page 7 of 12Marciniec et al. Chemistry Central Journal  (2018) 12:55 
6. Since the chemical shift and multiplicity of two meth-
ylene groups (H-10 and H-11) in the tetramethylene 
bridging units can provide information about the con-
formational preferences of tested compounds, 1H NMR 
studies for 2–5 were performed. In general, the 1H NMR 
spectra of azinesulfonamides analyzed in DMSO solu-
tions, were characterized by two multiplets separated by 
0.25–0.27  ppm, assigned to the protons of two central 
methylene groups (H-10 and H-11) of the butyl chain. 
This might suggest the bent conformation, which is in 
agreement with previous observations [17, 25]. The above 
inferences were confirmed by the nuclear Overhauser 
effect (NOE). This experimental evidence for the confor-
mations in solution of compounds 2–5 was provided by 
rotating frame Overhauser effect spectroscopy (ROESY) 
experiments conducted in DMSO; the significant NOE 
signals are indicated in Fig. 3. If the compounds were in 
their extended conformation, the interactions between 
the sulfonamide proton and H-11 would not be expected 
to exist. Alternatively, in a bent conformation the closer 
spatial arrangements of these protons could explain the 
observed NOE signals. In the obtained spectra, char-
acteristic cross-peaks from the sulfonamide proton 
and methylene protons of the alkyl chain (H-11) were 
assigned the bent conformation. On the other hand, the 
appearance of weak interactions between H-9 and H-11 
protons indicates the possibility of equilibrium between 
the bent and the extended conformation. However, the 
lack of interactions between the azine moiety and the 
phenyl protons (from arylpiperazine) definitely excludes 
the folded conformation of compounds and stacking 
interaction in solution.
Furthermore, 2D-NOE experiments confirmed the 
cross peaks for intramolecular interactions, are thus in 
agreement with bent conformations in solution. Molecu-
lar modeling studies of azinesulfonamides 2–6 were sub-
sequently carried out with Gaussian 16 computer code. 
Conformational preferences were explored using the 
parameters for either the isolated “gas phase” or water 
continuum. Among the structures produced, the free 
energetically favored conformations indicated the meth-
ylene C9 and C10 bridging groups in a synclinal arrange-
ment with aromatic portions far away from each other, 
consistent with NMR experimental data (Additional 
file  1: Table  S4 and Figure S2). Higher energy extended 
structures were also generated, which were approxi-
mately 85 kJ/mol above the bent structures at most. This 
data constituted the basis for further molecular modeling 
and prediction of the ligands’ binding orientation to a 
receptor binding site.
Molecular modeling
To complete the examination of the conformational 
preferences of the studied compounds, molecular dock-
ing of azinesulfonamides was performed with the use of 
recently developed 5-HT7 and 5-HT1A homology models, 
built on a dopaminergic  D3 receptor template (PDB ID: 
3PBL) [13, 26–31]. Next, the combination of the QPLD 
with MM-generalized-born/surface area (MM/GBSA) 
calculations from the Schrödinger Suite was used to 
obtain ligand–receptor complexes, as this approach is 
suitable to describe the anisotropy of the electron density 
of halogen atoms, which is a key feature during halogen 
bond examination [32]. The obtained complexes (Fig. 5) 
exhibit highly consistent binding modes, involving a 
salt-bridge with Asp3.32 and interactions formed by the 
aromatic moiety of the arylpiperazine fragment (CH–π) 
with the side chain of Phe6.52. The higher affinity of 5 
(with 2,3-dichloro substituent) for 5-HT7 and 5-HT1A 
than its unsubstituted analog 1 might be explained by 
the ability of chlorine to stabilize the ligand–recep-
tor complex by the formation of a halogen bond (Cl∙∙∙O 
distance = 3.38  Å, σ-hole angle = 177.6° for 5-HT7R, 
and Cl∙∙∙O distance = 3.62  Å, σ-hole angle = 167.9° for 
5-HT1AR, respectively) with the backbone carbonyl 
group of Thr5.39 (Fig. 5).
The change in binding affinities for compound 5 is 
probably related to the mutual orientation of the pip-
erazine plane and the phenyl ring. In complexes of com-
pound 5 with receptors, the angle between both rings 
maintains high values (57.4° for 5-HT1A and 67.3° for 
5-HT7, respectively). Interestingly, in both receptors a 
higher increase in binding free energy (∆∆G) was noted 
for the dihalogenated (5) than dimethylated (4) analog 
of compound 1, indicating a significant role of halogen 
bonding in ligand–receptor interaction.
Among all of the docked poses, the bent conformations 
predominated and no extended arrangements were found 
(Additional file 1: Table S4). This is in general agreement 
with the parameters of related crystal structures as well 
as with NMR experimental data.
Conclusions
The present paper has reported the preparation and per-
formance of biological and conformational studies for a 
small series of azinesulfonamide analogs of aripiprazole, 
with tri- and tetra-methylene spacers and phenylpipera-
zine substituted with chlorine and methyl groups. Among 
azine fragments, the 7-quinolinyl fragment was the most 
favorable for interaction with 5-HT1ARs. Moreover, the 
introduction of a chlorine atom or atoms into the phe-
nyl ring significantly impacted the affinity for 5-HT1A and 
5-HT7Rs. Furthermore, conformational studies (X-ray 
analysis and 2D NMR experiments) of the polimethylene 
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chain of LCAPs revealed that the bent conformation in 
a solid and in solutions is favorable. The above observa-
tions are compatible with the molecular modeling study 
performed for 2–6.
Docking analysis of the tested compounds suggest that 
all LCAPs were consequently docked in their bent con-
formations, with synclinal C9–C10 torsion, and that they 
bind to 5-HT1A and 5-HT7 receptors in a similar way. 
Our structural investigations organize knowledge about 
the conformational preferences of selected serotonin 
receptor ligands in different environments, and show that 
potentially bioactive conformations could be predicted 
by X-ray spectrometry and calculations using appropriate 
solvent simulated semi-empirical methods.
Experimental
Methods
Organic solvents (from Aldrich and Chempur) were of 
reagent grade and were used without purification.
Purity of the synthesized compounds was confirmed 
by TLC performed on Merck silica gel 60 F254 alu-
minium sheets (Merck, Darmstadt, Germany). Spots 
were detected by their absorption under UV light 
(k = 254 nm).
Analytical HPLC were run on a Waters Alliance HPLC 
instrument, equipped with a Chromolith SpeedROD 
column (4.6 × 50 mm). Standard conditions were eluent 
system A (water/0.1% TFA), system B (acetonitrile/0.1% 
TFA). A flow rate of 5  mL/min and a gradient of 
(0–100)  % B over 3  min were used. Detection was per-
formed on a PDA detector. Retention times (tR) are given 
in minutes.
NMR Spectra were recorded on Bruker Ascend 600 
spectrometer operating at 600.22 and 125.12  MHz for 
1H and 13C nuclei, respectively, in DMSO-d6 solution. 
Two-dimensional 1H-1H (COSY and NOESY) and 1H-
13C (HSQC and HMBC) and NOE (ROESY) experiments 
were performed using standard Bruker software. J values 
are in hertz (Hz), and splitting patterns are designated as 
follows: s (singlet), brs (broad singlet) d (doublet), t (tri-
plet), m (multiplet).
Mass spectrometry analyses—samples were prepared 
in acetonitrile/water (10/90  v/v) mixture. The LC/MS 
system consisted of a Waters Acquity UPLC, coupled 
to a Waters TQD mass spectrometer (electrospray ioni-
zation mode ESI-triple quadrupole (QqQ). All other 
analyses were carried out using a Acquity UPLC BEH 
C18, 50 × 2.1  mm reversed-phase column. A flow rate 
of 0.3  mL/min and a gradient of (5–95)% B over 5  min 
was used. Eluent A:water/0.1%  HCO2H; eluent B: ace-
tonitrile/0.1%  HCO2H. Nitrogen was used for both 
nebulizing and drying gas. LC/MS data were obtained 
by scanning the first quadrupole in 0.5 s in a mass range 
from 100 to 700 m/z; 10 scans were summed up to pro-
duce the final spectrum.
Fig. 5 Superposition of the poses of compounds 1 (yellow), 4 (magenta), and 5 (cyan) against putative halogen binding pocket interaction spheres 
for 5-HT7 (a) and 5-HT1A (b) receptors, respectively. The chlorine–oxygen theoretical interaction spheres illustrate the projected qualities of the 
formed ligand–receptor halogen bonds. The applied methodology is described by Wilcken et al. [33]
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Elemental analyses were found within ± 0.4% of the 
theoretical values. Melting points (mp) were determined 
with a Buchi apparatus and are uncorrected.
Column chromatography separations were carried out 
on column with Merck Kieselgel 60 or Aluminium oxide 
90, neutral (70–230 mesh). Purification of compounds 
was performed on silica gel (irregular particles 40–63 lm, 
Merck Kieselgel 60).
General procedure for the preparation of compounds 1, 2, 
and 4
The starting 1-(4-aminobutyl)-4-phenylpiperazine (9), 
1-(4-aminobutyl)-4-(3-chlorophenyl)piperazine (10), 
1-(4-aminobutyl)-4-(2,3-dichlorophenyl)piperazine (11), 
1-(4-aminobutyl)-4-(2,3-dimethylphenyl)piperazine 
(12), and 1-(3-aminopropyl)-4-(2,3-dichlorophenyl)pip-
erazine (13) were synthesized according to the Gabriel 
method. A mixture of the appropriate N-(ω-aminoalkyl)-
phenylpiperazine (9–13) (1.0  mmol) in  CH2Cl2 (7  mL) 
and DIEA (2.4  mmol) was cooled down (ice bath), and 
azinesulfonyl chloride 7 or 8 (1.2  mmol) was added at 
0 °C in one portion. The reaction mixture was stirred for 
6 h under cooling. Then, the solvent was evaporated and 
the sulfonamides were separated by column chromatog-
raphy using  SiO2 and a mixture of  CH2Cl2/MeOH = 9/0.7 
or 9/0.5, as an eluting system. Free bases were then con-
verted into the hydrochloride salts by treatment of their 
solution in anhydrous ethanol with 1 M HCl in dioxane. 
The LC/MS of the identified compounds 1–6 exceeded 
purity of 98%.
N-(4-(4-phenyl)piperazin-1-yl)butyl)
isoquinoline-3-sulfonamide hydrochloride (1)
Yield 84%; m.p. 198–9  °C; 1H NMR δ: 1.43–1.46 (m, 
2H, H-10), 1.68–1.72 (m, 2H, Hz, H-11), 2.94 (td, 2H, 
J = 6.6  Hz, J = 6.0  Hz, H-9), 3.05–3.49 (m, 10H, 10H, 
H-12, H-13, H-14, H-15 and H-16), 7.07–7.18 (m, 5H, 
Ph), 7.88 (dd, 1H, J = 8.4 Hz, J = 7.8 Hz, H-6), 7.93–7.99 
(m, 2H, H-7 and –SO2NH–), 8.25–8.30 (m, 2H, H-5 and 
H-8), 8.52 (s, 1H, H-4), 9.49 (s, 1H, H-1), 10.95 (brs, 1H, 
–CH2NH+(CH2CH2)2N–); 13C NMR δ: 20.8 (C-11), 27.1 
(C-10), 42.7 (C-9), 48.3 (C-14 and C-15), 51.8 (C-13 and 
C-16), 55.3 (C-12), 120.3 (C-4), 125.5 (Ph), 128.3 (Ph), 
128.4 (C-5), 128.5 (C-3), 128.6 (Ph), 129.4 (C-8), 130.5 
(C-6), 132.6 (C-7), 135.4 (C-4a), 139.3 (Ph), 151.5 (C-8a), 
153.9 (C-1).
N-(4-(4-(3-chlorophenyl)piperazin-1-yl)butyl)
isoquinoline-3-sulfonamide hydrochloride (2)
Yield 89%; m.p. 246–7 °C; 1H NMR δ: 1.43–1.45 (m, 2H, 
H-10), 1.67–1.71 (m, 2H, H-11), 2.94 (td, 2H, J = 6.6 Hz, 
J = 6.0  Hz, H-9), 3.05–3.49 (m, 10H, H-12, H-13, H-14, 
H-15 and H-16), 6.87 (d, 1H, J = 7.2 Hz, Ph), 6.95 (d, 1H, 
J = 7.8 Hz, Ph), 7.07 (s, 1H, Ph), 7.25 (dd, 1H, J = 7.8 Hz, 
J = 7.2 Hz, Ph), 7.90 (dd, 1H, J = 8.4 Hz, J = 7.8 Hz, H-6), 
7.93–7.98 (m, 2H, H-7 and –SO2NH–), 8.26–8.33 (m, 
2H, H-5 and H-8), 8.53 (s, 1H, H-4), 9.48 (s, 1H, H-1), 
10.06 (brs, 1H, –CH2NH+(CH2CH2)2N–); 13C NMR δ: 
22.6 (C-11), 27.1 (C-10), 42.7 (C-9), 45.4 (C-14 and C-15), 
50.9 (C-13 and C-16), 55.4 (C-12), 114.7 (Ph), 115.8 (Ph), 
120.3 (C-4 and Ph), 128.4 (C-5), 128.5 (C-8), 129.4 (C-3), 
130.5 (Ph), 131.1 (C-6), 132.6 (C-7), 134.4 (Ph), 135.4 
(C-4a), 147.9 (Ph), 151.5 (C-8a), 154.0 (C-1).
N-(4-(4-(2,3-dimethylphenyl)piperazin-1-yl)butyl)
isoquinoline-3-sulfonamide hydrochloride (4)
Yield 86%; m.p. 215–6  °C; 1H NMR δ: 1.44–1.48 (m, 
2H, H-10), 1.71–1.75 (m, 2H, J = 6.6  Hz, H-11), 2.15 (s, 
3H, –CH3), 2.21 (s, 3H, –CH3), 2.93 (td, 2H, J = 6.6 Hz, 
J = 6.0  Hz, H-9), 3.08–3.46 (m, 10H, H-12, H-13, H-14, 
H-15 and H-16), 6.87–6.91 (m, 2H, Ph), 7.04–7.09 (m, 
1H, Ph), 7.86–7.99 (m, 3H, H-6, H-7 and –SO2NH), 
8.25–8.31 (m, 2H, H-5 and H-8), 8.53 (s, 1H, H-4), 9.49 
(s, 1H, H-1), 10.93 (brs, 1H, –CH2NH+(CH2CH2)2N–); 
13C NMR δ: 14.1 (–CH3), 20.7 (–CH3), 20.8 (C-11), 27.1 
(C-10), 42.7 (C-9), 48.9 (C-14 and C-15), 51.7 (C-13 and 
C-16), 55.4 (C-12), 116.9 (Ph), 120.3 (C-4), 125.9 (Ph), 
126.3 (Ph), 128.4 (C-5), 128.5 (C-3), 129.4 (C-8), 130.5 
(C-6), 131.0 (Ph), 132.6 (C-7), 135.4 (C-4a), 138.1 (Ph), 
150.3 (Ph), 151.5 (C-8a), 153.9 (C-1).
X-ray crystal structures determination
Crystals of 2–6 were obtained by slow evaporation of the 
solvent under ambient conditions from ethanol: water 
mixture in ratio of 5:1.
X-ray diffraction data were collected using SuperNova 
diffractometer with Cu Kα radiation (λ = 1.54184 Å) for 
crystal 2 and with Mo Kα radiation (λ = 0.71073  Å) for 
crystals 3–6, with the CrysAlisPro software [34]. Data 
were processed with the same program. Experiments 
were performed at 100  K excepting crystal of 4, which 
was measured at room temperature. The phase prob-
lem was solved by direct methods with SHELXS-97 
[35]. The model parameters were refined by full-matrix 
least-squares on  F2 using SHELXL-2014/7 [35]. All non-
hydrogen atoms were refined anisotropically. Hydrogen 
atoms were introduced to all structures by appropriate 
rigid body constraints (AFIX 23, AFIX 43 or AFIX 137) 
with temperature factors  Uiso(H) equal to 1.2Ueq(C) for 
aromatic and methylene hydrogen atoms or 1.5Ueq(C) 
for methyl hydrogen atoms. Hydrogen atoms which take 
part in the hydrogen bonds were located in the calculated 
positions and then freely refined. Due to severely disor-
dered solvent in crystal of 2, the SQUEEZE program was 
used [36]. All crystallographic data for presented struc-
tures are shown in Additional file 1: Table S5. The figures 
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showing asymmetric units were made with Jmol [37]. 
The figure presenting structural motives were made with 
Mercury [38].
In vitro evaluation
Cell culture and preparation of cell membranes 
for radioligand binding assays
HEK293 cells with stable expression of human 5-HT1A, 
5-HT6, 5-HT7b and  D2L receptors (prepared with the 
use of Lipofectamine 2000) were maintained at 37  °C 
in a humidified atmosphere with 5%  CO2 and grown in 
Dulbecco’s Modifier Eagle Medium containing 10% dia-
lyzed fetal bovine serum and 500  µg/ml G418 sulfate. 
For membrane preparation, cells were subcultured in 
150 cm2 flasks, grown to 90% confluence, washed twice 
with prewarmed to 37 °C phosphate buffered saline (PBS) 
and pelleted by centrifugation (200g) in PBS containing 
0.1 mM EDTA and 1 mM dithiothreitol. Prior to mem-
brane preparation, pellets were stored at − 80 °C.
Radioligand binding assays
Cell pellets were thawed and homogenized in 10 volumes 
of assay buffer using an Ultra Turrax tissue homogenizer 
and centrifuged twice at 35,000g for 15 min at 4 °C, with 
incubation for 15 min at 37  °C in between. The compo-
sition of the assay buffers was as follows: for 5-HT1AR: 
50  mM Tris HCl, 0.1  mM EDTA, 4  mM  MgCl2, 10  µM 
pargyline and 0.1% ascorbate; for 5-HT6R: 50  mM Tris 
HCl, 0.5  mM EDTA and 4  mM  MgCl2, for 5-HT7bR: 
50 mM Tris HCl, 4 mM  MgCl2, 10 µM pargyline and 0.1% 
ascorbate; for dopamine  D2LR: 50  mM Tris HCl, 1  mM 
EDTA, 4 mM  MgCl2, 120 mM NaCl, 5 mM KCl, 1.5 mM 
 CaCl2 and 0.1% ascorbate. All assays were incubated in 
a total volume of 200  µl in 96-well microtitre plates for 
1  h at 37  °C, except 5-HT1AR which were incubated at 
room temperature. The process of equilibration was ter-
minated by rapid filtration through Unifilter plates with 
a FilterMate Unifilter 96-Harvester (PerkinElmer). The 
radioactivity bound to the filters was quantified on a 
Microbeta TopCount instrument (PerkinElmer, USA). 
For competitive inhibition studies the assay samples 
contained as radioligands (PerkinElmer, USA): 2.5  nM 
 [3H]-8-OH-DPAT (135.2  Ci/mmol) for 5-HT1AR; 2  nM 
 [3H]-LSD (83.6 Ci/mmol) for 5-HT6R; 0.8 nM  [3H]-5-CT 
(39.2  Ci/mmol) for 5-HT7R or 2.5  nM  [3H]-raclopride 
(76.0  Ci/mmol) for  D2LR. Non-specific binding was 
defined with 10  µM of 5-HT in 5-HT1AR and 5-HT7R 
binding experiments, whereas 10  µM of methiothepine 
or 10  µM of haloperidol were used in 5-HT6R and  D2L 
assays, respectively. Each compound was tested in trip-
licate at 7 concentrations  (10−10–10−4 M). The inhibition 
constants (Ki) were calculated from the Cheng–Prusoff 
equation [39]. Results were expressed as means of at least 
two separate experiments.
Computational details
Geometry optimization
Ab initio calculations of the studied azinesulfonamides, 
using crystallographic data as starting point, were carried 
out with the Gaussian 16 (revision A.03) computer code 
[40] at the density functional theory (DFT, Becke3LYP 
[41]) level of theory using the 6–311 + G(d,p) basis sets. 
The conformational behavior of these systems in water 
was examined using the CPCM solvation method [42, 
43].
Molecular docking
3-Dimensional structures of the ligands were prepared 
using LigPrep v3.6 [44], and the appropriate ionization 
states at pH 7.4 ± 1.0 were assigned using Epik v3.4 [45]. 
The Protein Preparation Wizard was used to assign the 
bond orders, appropriate amino acid ionization states 
and to check for steric clashes. The receptor grid was 
generated (OPLS3 force field [46]) by centering the grid 
box with a size of 12 Å on Asp3.32 residue. Docking was 
performed by quantum-polarized ligand docking (QPLD) 
procedure [47] involves the QM-derived ligand atomic 
charges in the protein environment at the B3PW91/cc-
pVTZ level. Only ten best poses per ligand returned by 
the procedure were considered.
Binding free energy calculations
MM/GBSA (Generalized-Born/Surface Area) was used 
to calculate the binding free energy based on the ligand–
receptor complexes generated by the QPLD procedure. 
The ligand poses were minimized using the local optimi-
zation feature in Prime, the flexible residue distance was 
set to 4.0  Å from a ligand pose, and the ligand charges 
obtained in the QPLD stage were used. The energies of 
complexes were calculated with the OPLS3 force field 
and Generalized-Born/Surface Area continuum solvent 
model. To assess the influence of a given substituent 
on the binding, the ∆∆G was calculated as a difference 
between binding free energy (∆G) of unsubstituted at 
phenyl ring sulfonamide 1 and investigated analogs 3, 4, 
and 5.
Plotting interaction spheres for halogen bonding
To visualize (plotting interaction spheres) the possi-
ble contribution of halogen bonding to ligand–receptor 
complexes, the halogen bonding web server was used 
(access Oct 01, 2017, http://www.halog enbon ding.com/).
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